Cargando…
An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption
Dulaglutide is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist that has shown a durable glycemic efficacy as well as beneficial effects on body weight and major adverse cardiovascular events (MACE) outcomes, making it an important option for the treatment of type 2 diabetes...
Autores principales: | Kyriakos, Georgios, Diamantis, Evangelos, Memi, Eleni, Elefsiniotis, Ioannis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864188/ https://www.ncbi.nlm.nih.gov/pubmed/35223310 http://dx.doi.org/10.7759/cureus.21536 |
Ejemplares similares
-
Morbilliform Rash: An Uncommon Herald of SARS-CoV-2
por: Kulkarni, Radhika B, et al.
Publicado: (2020) -
Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
por: Alhammad, Norah S, et al.
Publicado: (2022) -
Morbilliform Eruptions in the Hospitalized Child
por: Haber, Jessica S., et al.
Publicado: (2022) -
Doxycycline-Associated Dual Cutaneous Adverse Reaction to the Drug (CARD): Case Report of Concurrent Photosensitivity and Morbilliform Exanthem to Doxycycline
por: Jacob, Joanne S, et al.
Publicado: (2020) -
An asymmetric morbilliform eruption in an adult male
por: Yelich, Allyson, et al.
Publicado: (2022)